BrainChild Bio raises $119M Series A to fund pivotal Phase 2 of CAR T BCB-276 for deadly pediatric DIPG

BrainChild Bio raised $119 million in a Series A to advance CAR T therapies for pediatric central nervous system cancers, funding a pivotal Phase 2 trial of lead asset BCB-276 for diffuse intrinsic pontine glioma (DIPG) and preclinical work on BCB-214.

More: FinSMEs, Endpoints News, Fierce Biotech, GEN - Genetic Engineering and Biotechnology News, American Chemical Society, GeekWire, WebProNews, BrainChild Bio, Inc.
Comments: Kyle LaHucik, Alex Philippidis

No comments yet.